BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger

Stock Information for Idera Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Idera Pharmaceuticals Acquires Aceragen
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.